Introduction
============

Early percutaneous coronary intervention (PCI) is the most effective treatment for acute coronary syndrome (ACS, ST-elevation myocardial infarction (STEMI), non-STEMI, unstable angina pectoris) complicated by states Killip 3 and 4.

Methods
=======

A total of 1,187 patients suffering from high-risk acute coronary syndrome (hrACS) were treated in our center in 2005. States Killip 3 and 4 have developed perioperatively in 186 of these patients. International studies have proven high mortality in these patient groups -- especially in state Killip 4. Our aim was to analyze the inhospital mortality of the state Killip 3 and 4 patient group treated in our center in 2005.

Results
=======

Seven hundred and two patients with STEMI and 485 patients with hrACS were admitted to our center in 2005. The mortality of these patients was 4.84% (STEMI) and 3.71% (hrACS), and the main cause of this mortality (37.7%) was the Killip 3/4 state, which was observed in 11.9% of the STEMI patients and in 17.9% of hrACS patients (*n*= 84 and 87). The mean age of the Killip 3/4 patients was 70 ± 10 years. Angiologically successful PCI was performed in 97.9% of the cases. The ratio of revascularized coronaries was left anterior descending coronary artery (LAD): 66 (35.9%), right coronary artery (RCA): 33 (17.9%), circumflex coronary artery (CX): 28 (15.2%), PCI in left main coronary artery: 28 (12.5%), LAD + CX: 15 (8.15%), RCA + LAD: 7 (3.8%), CX + RCA: 6 (3.26%), venous bypass graft: 2 (1.1%). No PCI was performed in two cases. Adjuvant therapies of intraaortic balloon counterpulsation in 67 (36%), mechanical ventilation in 62 (33.3%), continuous veno-venous hemofiltration in 12 (6.45%), and levosimendan therapy in 86 (46.2%) patients were used. Ten (5.4%) of the patients had advanced adult life support (cardiopulmonary resuscitation) (AALS) before arrival at our center, and AALS was performed in the perioperative period in 16 (8.6%) patients. The early inhospital mortality of hrACS aggravated by state Killip 3/4 was 10.7% (20 patients) -- according to subgroup: Killip 3: 0.06%; Killip 4: 30.5%.

Conclusion
==========

The prognosis of state Killip 3/4 and successive multiorgan failure as the high-mortality complication of hrACS can be improved by early successful PCI, and the concomitant pharmacologic and nonpharmacologic supportive therapy.
